Skip to main content
August 05, 2019
Sunovion Pharmaceuticals announced last week that the Food and Drug Administration (FDA) has accepted its New Drug Application for dasotraline for the treatment of moderate to severe binge eating disorder. The FDA's action date for the novel dopamine and norepinephrine reuptake inhibitor is May 14…
August 05, 2019
A new study suggests that a more conservative approach to medicating infants born with neonatal opioid withdrawal syndrome (NOWS) can lead to shorter hospital stays and more effective outcomes.
August 02, 2019
An Ohio partnership designed to reduce opioid use in the hard-hit state conducted a training this week to encourage physicians, nurse practitioners and physician assistants to offer medication-assisted treatment in a variety of care settings. The Healthy State Alliance, a joint effort of The Ohio…
July 31, 2019
A new website in California is serving as a hub for treatment providers and the public to access information about the state's response to the opioid crisis. The research and consulting firm Health Management Associates has spearheaded development of the Addiction Free CA site as it works with…
July 29, 2019
A federal judge last week ordered the Food and Drug Administration (FDA) to reconsider its decision to grant market exclusivity to the first approved injectable formulation of buprenorphine for opioid dependence.
Back to Top